Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Terminated 2Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 31Gastrointestinal 14Tumor-Agnostic 7Thoracic 6Other solid neoplasm 5Head & Neck 5CNS 4Sarcoma 3Endocrine 3Dermatologic 3Gynecologic 2Breast 2Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1

Conditions

Melanoma 3Skin Neoplasms 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Axitinib × Dermatologic × Clear all
NCT01321437 2021-01-20

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

University of California, Irvine

Phase 2 Completed
11 enrolled 12 charts
Dermatologic

Melanoma

NCT01174238 2018-06-08

A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma

University of California, San Francisco

Phase 2 Completed
40 enrolled 10 charts
Dermatologic

Melanoma

NCT00094107 2012-06-26

Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

Pfizer

Phase 2 Completed
32 enrolled 9 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡